U.S. Markets close in 4 hrs 39 mins

GenVec, Inc. (GNVC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.680.00 (0.00%)
At close: 4:00PM EDT
People also watch
CYCCHEBCRISCTICCYTR
Interactive chart
Previous Close6.68
Open6.60
Bid0.00 x
Ask0.00 x
Day's Range6.59 - 6.68
52 Week Range0.27 - 10.44
Volume863
Avg. Volume33,292
Market Cap15.19M
Beta2.36
PE Ratio (TTM)-1.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
    Capital Cube17 days ago

    GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

    Categories: Yahoo FinanceGet free summary analysis GenVec, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of GenVec, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Novavax, Inc., Novartis AG Sponsored ADR, Merck & Co., Inc., Astrazeneca PLC Sponsored ADR and Johnson & Johnson (EBS-US, PFE-US, NVAX-US, ... Read more (Read more...)

  • American City Business Journalslast month

    GenVec investor alleges misleading financial disclosures ahead of Intrexon acquisition

    An investor in Gaithersburg gene therapy company GenVec Inc. sued the company and its board this week following a deal inked earlier this year to be acquired by Germantown-based Intrexon Corp. Intrexon (XON) and GenVec CEO Douglas Swirsky are also named in the suit. The case, brought by investor James Hoose, alleges GenVec issued misleading disclosures in a Securities and Exchange Commission filing on March 17 to convince shareholders to vote in favor of the proposed deal.

  • GenVec, Inc. :GNVC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube2 months ago

    GenVec, Inc. :GNVC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis GenVec, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of GenVec, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Novavax, Inc., Novartis AG Sponsored ADR, Merck & Co., Inc., Sangamo Therapeutics, Inc., Astrazeneca PLC Sponsored ADR, NanoViricides, Inc., Johnson & ... Read more (Read more...)